In focus · trending topic

BioMarin

23 stories · following the connections

BioMarin to Attend Upcoming Investor Conferences

By Nasdaq OMXAug 31, 2016, 12:30 PM UTC

Forbes Ranks BioMarin 10th Most Innovative Company in the World

By Nasdaq OMXAug 24, 2016, 1:54 PM UTC

BioMarin Announces Pricing of Public Offering of Common Stock

By Nasdaq OMXAug 9, 2016, 1:00 PM UTC

BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program

By Nasdaq OMXApr 20, 2016, 12:30 PM UTC

BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on April 20th in New York

By Nasdaq OMXApr 18, 2016, 12:30 PM UTC

BioMarin Receives European Orphan Drug Designation for BMN 270, First Investigational AAV-Factor VIII Gene Therapy for Patients with Hemophilia A

By Nasdaq OMXMar 24, 2016, 12:30 PM UTC

BioMarin to Attend Three Upcoming Investor Conferences in March

By Nasdaq OMXMar 3, 2016, 1:30 PM UTC

BioMarin Announces Positive Data From Cerliponase Alfa Program for Treatment of CLN2 Disease, a Form of Batten Disease, at 12th Annual WORLDSymposium(TM) 2016

By Nasdaq OMXMar 3, 2016, 12:05 AM UTC